Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for CTLA-4-Ig (compound)
Most Correlated Studies
- CD4-positive T cells and antigen presenting cells from OVA TCR mice treated with abatacept
- T-cells expression after treatment with leukocyte costimulatory blockade antibodies
- Drug target sets for approved compounds
- Germinal B cells from spleen of systemic lupus erythematosus mice treated with CTLA4Ig & anti-CD40L
- Whole blood of rheumatoid arthritis patients treated with abatacept
Most Relevant Literature
- Rapid response to abatacept in treatment-resistant pansclerotic morphoea.
- Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
- Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Doubl…
- Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse even…
- A review on applications of abatacept in systemic rheumatic diseases.
Most Relevant Clinical Trials
- Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects
- Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
- Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
- Phase IIIB Subcutaneous Missed Dose Study
- A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
